Trials / Recruiting
RecruitingNCT06514521
Post Marketing Study on Pluvicto in Korea
A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 278 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Post marketing study on Pluvicto in Korea
Detailed description
This is open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Pluvicto in patients with mCRPC in the real-world setting in South Korea.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Lutetium vipivotide tetraxetan | This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement. |
Timeline
- Start date
- 2025-04-18
- Primary completion
- 2028-05-31
- Completion
- 2028-05-31
- First posted
- 2024-07-23
- Last updated
- 2025-12-30
Locations
8 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06514521. Inclusion in this directory is not an endorsement.